company background image
REGN

Regeneron PharmaceuticalsNasdaqGS:REGN Stock Report

Market Cap

US$57.5b

7D

0.6%

1Y

-7.8%

Updated

16 Oct, 2021

Data

Company Financials +
REGN fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance5/6
Financial Health6/6
Dividends0/6

REGN Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide.

Regeneron Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Regeneron Pharmaceuticals
Historical stock prices
Current Share PriceUS$553.24
52 Week HighUS$441.00
52 Week LowUS$686.62
Beta0.21
1 Month Change-15.30%
3 Month Change-5.14%
1 Year Change-7.75%
3 Year Change41.92%
5 Year Change52.19%
Change since IPO2,518.89%

Recent News & Updates

Oct 05
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Safely

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Safely

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

Oct 04

Regeneron Pharmaceuticals: Undervalued Cash Generating Machine

REGN has a strong economic moat protected by technology and patents. Profitability and strength of balance sheet are well above industry average. Market is overestimating the impact of tapering sales of their COVID treatment and potential biosimilars to Eylea. Current stock price offers 60-140% upside.

Shareholder Returns

REGNUS BiotechsUS Market
7D0.6%1.0%2.0%
1Y-7.8%12.5%27.6%

Return vs Industry: REGN underperformed the US Biotechs industry which returned 12.4% over the past year.

Return vs Market: REGN underperformed the US Market which returned 27.6% over the past year.

Price Volatility

Is REGN's price volatile compared to industry and market?
REGN volatility
REGN Beta0.21
Industry Beta0.98
Market Beta1

Stable Share Price: REGN is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: REGN's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19889,635Leonard Schleiferhttps://www.regeneron.com

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults.

Regeneron Pharmaceuticals Fundamentals Summary

How do Regeneron Pharmaceuticals's earnings and revenue compare to its market cap?
REGN fundamental statistics
Market CapUS$57.52b
Earnings (TTM)US$6.21b
Revenue (TTM)US$12.20b

9.3x

P/E Ratio

4.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
REGN income statement (TTM)
RevenueUS$12.20b
Cost of RevenueUS$4.52b
Gross ProfitUS$7.68b
ExpensesUS$1.48b
EarningsUS$6.21b

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Nov 04, 2021

Earnings per share (EPS)59.69
Gross Margin62.98%
Net Profit Margin50.87%
Debt/Equity Ratio13.1%

How did REGN perform over the long term?

See historical performance and comparison

Valuation

Is Regeneron Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

38.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: REGN ($553.24) is trading below our estimate of fair value ($891.75)

Significantly Below Fair Value: REGN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: REGN is good value based on its PE Ratio (9.3x) compared to the US Biotechs industry average (23.6x).

PE vs Market: REGN is good value based on its PE Ratio (9.3x) compared to the US market (18.2x).


Price to Earnings Growth Ratio

PEG Ratio: REGN's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: REGN is overvalued based on its PB Ratio (3.8x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Regeneron Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?

-6.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: REGN's earnings are forecast to decline over the next 3 years (-6.6% per year).

Earnings vs Market: REGN's earnings are forecast to decline over the next 3 years (-6.6% per year).

High Growth Earnings: REGN's earnings are forecast to decline over the next 3 years.

Revenue vs Market: REGN's revenue is expected to decline over the next 3 years (-1.9% per year).

High Growth Revenue: REGN's revenue is forecast to decline over the next 3 years (-1.9% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: REGN's Return on Equity is forecast to be high in 3 years time (20.8%)


Past Performance

How has Regeneron Pharmaceuticals performed over the past 5 years?

34.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: REGN has a high level of non-cash earnings.

Growing Profit Margin: REGN's current net profit margins (50.9%) are higher than last year (40.4%).


Past Earnings Growth Analysis

Earnings Trend: REGN's earnings have grown significantly by 34.6% per year over the past 5 years.

Accelerating Growth: REGN's earnings growth over the past year (108%) exceeds its 5-year average (34.6% per year).

Earnings vs Industry: REGN earnings growth over the past year (108%) exceeded the Biotechs industry 4.9%.


Return on Equity

High ROE: REGN's Return on Equity (41%) is considered outstanding.


Financial Health

How is Regeneron Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: REGN's short term assets ($13.3B) exceed its short term liabilities ($3.7B).

Long Term Liabilities: REGN's short term assets ($13.3B) exceed its long term liabilities ($2.6B).


Debt to Equity History and Analysis

Debt Level: REGN's debt to equity ratio (13.1%) is considered satisfactory.

Reducing Debt: REGN had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Debt Coverage: REGN's debt is well covered by operating cash flow (114.8%).

Interest Coverage: REGN's interest payments on its debt are well covered by EBIT (91.3x coverage).


Balance Sheet


Dividend

What is Regeneron Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate REGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate REGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if REGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if REGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of REGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Leonard Schleifer (68 yo)

33.75yrs

Tenure

US$135,350,121

Compensation

Dr. Leonard S. Schleifer, M.D., Ph D., founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988. Dr. Schleifer served as the Chairman of Regeneron P...


CEO Compensation Analysis

Compensation vs Market: Leonard's total compensation ($USD135.35M) is above average for companies of similar size in the US market ($USD11.20M).

Compensation vs Earnings: Leonard's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: REGN's management team is considered experienced (2.5 years average tenure).


Board Members

Experienced Board: REGN's board of directors are seasoned and experienced ( 19.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: REGN insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Regeneron Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Regeneron Pharmaceuticals, Inc.
  • Ticker: REGN
  • Exchange: NasdaqGS
  • Founded: 1988
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$57.519b
  • Shares outstanding: 103.97m
  • Website: https://www.regeneron.com

Number of Employees


Location

  • Regeneron Pharmaceuticals, Inc.
  • 777 Old Saw Mill River Road
  • Tarrytown
  • New York
  • 10591-6707
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/16 22:25
End of Day Share Price2021/10/15 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.